Document:

Exhibit 10.4

 

FORM OF 

LYONDELLBASELL EXECUTIVE SEVERANCE PLAN 

PARTICIPATION AGREEMENT

 

This Executive Severance Plan
Participation Agreement (the “Participation Agreement”) is entered into effective as of __________________________, 20__ [NTD:
Start Date] (the “Participation Date”), by and between Lyondell Chemical Company (the “Company”) and you (the
 “Participant”), pursuant to the LyondellBasell Executive Severance Plan (the “Plan” or “LYB Executive Severance
Plan”). The Participant agrees that the terms and conditions of this Agreement and the Plan will govern the Participant’s
rights with respect to the severance benefits provided under the Plan (the “Severance Benefits”), notwithstanding any contrary
provision in any employment agreement or other severance plan. The Participant and the Company agree to execute such further instruments
and to take such further action as may reasonably be necessary to carry out the intent of this Participation Agreement. Except as defined
in this Participation Agreement (including Exhibit A attached hereto), capitalized terms have the same meanings ascribed to them in the
Plan.

 

The Participant and the Company
have entered into this Participation Agreement and have agreed to the terms and conditions included in Exhibit A as an express incentive
for the Participant and the Company to enter into the Participation Agreement and in consideration for the Company or any of its affiliates
providing (i) the consideration set forth in the Participation Agreement and (ii) Confidential Information to the Participant, to
further protect the trade secrets and Confidential Information disclosed or entrusted to the Participant, to protect the business goodwill
of the Company and its affiliates, to protect the business opportunities disclosed or entrusted to the Participant, and to protect the
other legitimate business interests of the Company and its affiliates. In executing this Participation Agreement, the Participant expressly
acknowledges and agrees that (a) the Participation Agreement aligns the Participant’s interests with the Company’s and its
affiliates’ long-term business interests and creates a further incentive for the Participant to build the Company’s and its
affiliates’ goodwill, and (b) the provisions contained in Exhibit A are reasonably related to the Company’s and its affiliates’
legitimate interests in protecting their goodwill. The Participant understands that the Company has hereby promised to provide to the
Participant Confidential Information during the Participant’s employment with the Company.

 

The Participant and the Company
also expressly agree that any long-term incentive awards that may hereafter be granted to the Participant pursuant to the LyondellBasell
Industries (“LYB”) Long-Term Incentive Plan (the “LTIP”) similarly aligns the Participant’s interests with
LYB’s and the Company’s long-term business interests and creates a further incentive for the Participant to build the Company’s
and LYB’s goodwill, and that the provisions contained in Exhibit A and Section 2 of this Agreement as they relate to such LTIP awards
are reasonably related to the Company’s and LYB’s legitimate interest in protecting its goodwill. Accordingly, Section 2 of
this Agreement (regarding recovery of payments) also applies to any awards made to the Participant under the LTIP to the extent such awards
(1) are granted after the Participant signs this Participation Agreement and (2) vest or become exercisable on account of termination
of employment for any reason other than the Participant’s death or disability.

 

     

     

    

 

The terms and conditions
of this Participation Agreement as offered herein must be accepted by the Participant prior to _____________________, 20____. Failure
to timely accept the terms by such time will result in immediate and irrevocable cancellation of the participation offered.

 

1.        Participation. In accordance with, and subject to, the terms and conditions of the Plan, the Company hereby allows the
Participant to participate in the LYB Executive Severance Plan.

 

2.        Covenants; Recovery of Payments. If
the Committee determines that the Participant has committed a breach of any of the Covenants set forth in Exhibit A, upon notice from
the Company, the Participant shall reimburse to the Company all or a portion of the Severance Benefits or LTIP payments, or both, subject
to this Participation Agreement, as the Committee deems appropriate under the circumstances. Such notice shall be provided within the
earlier to occur of one year after discovery of the alleged breach or the second anniversary of the Participant’s date of termination.

 

3.        Interpretation and Construction.This
Participation Agreement and the Plan shall be interpreted and construed to the fullest extent possible consistent with the LTIP and any
applicable grant letter or award agreement thereunder. In the event of a conflict between the terms of any such document and this Participation
Agreement, this Participation Agreement shall control. For the avoidance of doubt, LTIP awards are subject to the terms of this Participation
Agreement only to the extent they (a) are granted after the Participant signs this Participation Agreement and (b) vest or become exercisable
on account of termination of employment for any reason other than the Participant’s death or disability. Incentive compensation
awards issued by the Company or LYB pursuant to the LTIP or any other incentive program or arrangement shall remain subject to other provisions
of such other award agreements and incentive arrangements, which shall not be affected by this Participation Agreement.

 

4.        This
Participation Agreement is governed by Texas law, without giving effect to its conflicts of law principles. The Participant consents to
the jurisdiction of the Harris County District State Court in Houston, Texas, although the Company may choose to seek enforcement of the
Covenants and any other benefits provided under this Agreement in any jurisdiction where the Participant may be found.

 

[SIGNATURE PAGE TO FOLLOW]

 

    2

     

    

 

	LYONDELL
    CHEMICAL COMPANY	 	 
	 	 	 
	By:	 	 	Date:	 
	 	 	 
	 	[Insert Name and Title]	 	 
	 	 	 
	 	 	 
	PARTICIPANT	 	 
	 	 	 
	 	 	Date:	 
	 	 	 
	Peter
    Vanacker	 	 

 

    3

     

    

 

EXHIBIT A

 

TO LYONDELLBASELL EXECUTIVE SEVERANCE PLAN 

PARTICIPATION AGREEMENT

 

	1.	As used in this Exhibit A, the following terms have the meanings set out below:

 

“Business”
means the business in which the Company and its affiliates are engaged and for which the Participant has direct or indirect responsibilities
during the term of Participant’s employment with the Company or any affiliate.

 

“Competitor”
means any business or enterprise engaged in the Business.

 

“Confidential
Information” means any trade secret, proprietary or confidential information of the Company or its affiliates.

 

“Restricted Area”
means those locations for which the Participant had responsibility at any time during the twelve (12) months prior to termination of Participant’s
employment with the Company and including any geographical area in which the Company (a) conducts any portion of its Business and for
which Participant had responsibility, or (b) has plans to conduct any portion of its Business, where those plans are known to the
Participant.

 

2.       Subject
to the exceptions set forth in this Exhibit A, the Participant agrees and expressly promises that the Participant shall not, during the
Participant’s employment with the Company or its affiliates and for a period of one (1) year after the Participant’s
termination of employment with the Company and all affiliates (the “Prohibited Period”), regardless of the reason
for such termination, directly or indirectly, anywhere in the Restricted Area:

 

(a)     
carry on or engage in the Business in competition with the Company, or

 

(b)     
render services to, or be affiliated with, a Competitor.

 

3.       Nothing
herein shall prevent the Participant during the Prohibited Period from rendering professional services to a Competitor (but not as an
employee of a Competitor) or being affiliated with a diversified entity, so long as the Participant’s affiliation with that Competitor
or entity, as applicable, does not:

 

(a)     
cause the Participant to use or disclose any Confidential Information, and

 

(b)     
involve the Participant having direct or indirect responsibilities with respect to any aspect of the entity’s business that
engages in the Business.

 

	4.	The Participant agrees and expressly promises that, during the
Prohibited Period, the Participant shall not directly or indirectly:

 

(a)     
recruit, solicit or induce any employee, consultant, or independent contractor of the Company or any of its affiliates to terminate
or lessen such person’s employment or other relationship with the Company or any affiliate, or

 

     

     

    

 

(b)     
 directly or indirectly solicit any then-current customer or business partner of the Company or any affiliate to terminate, alter,
or modify its relationship with the Company or any affiliate.

 

	5.	Notwithstanding the restrictions in this Exhibit A, nothing
herein prohibits:

 

(a)     
the Participant from making general advertisements for employment or engagement, so long as such advertisements are not specifically
targeted at any employees, consultants, or independent contractors of the Company or any affiliate, or

 

(b)     
any other person or entity from hiring, inducing, or attempting to induce, solicit, or encourage any employee or other service
provider of the Company or any of its affiliates to leave their employ or service, provided that the Participant does not directly or
indirectly participate in or direct the prohibited activity and provided further that this clause (b) of paragraph 5 shall not apply
with respect to the solicitation of any employee of the Company who is at that time an executive officer of the Company or an employee
of the Company directly reporting to any such executive officer.

 

(c)     
Participant or any of Participant’s affiliates may own an aggregate of not more than 5% of the outstanding stock of any class
of any corporation, if such stock is listed on a national securities exchange or regularly traded in the over-the-counter market by a
member of a national securities exchange, without violating the provisions of this Exhibit A, provided that neither Participant nor any
of Participant’s affiliates has the power, directly or indirectly, to control or direct the management or affairs of any such corporation
and is not involved in the management of such corporation.

 

6.       The
Participant agrees that during the Prohibited Period, and at all times thereafter, the Participant will not, in public or in private and
whether orally or in writing, make (or encourage any other third party to make) any disparaging or defamatory comments regarding (or otherwise
place in a false light or criticize) the Company or any affiliate, or any of the Company’s or its affiliates’ business, products,
policies, decisions, or current or former directors, officers, members, partners, or employees in any respect or make any comments concerning
any aspect of the Participant’s relationship with the Company or any affiliate or any conduct or events that precipitated any termination
of the Participant’s employment with or service to the Company or any affiliate. However, the Participant’s obligations under
this Section 6 shall not prohibit the Participant from making a good faith report of possible violations of applicable law to any
governmental agency or entity, from making disclosures that are protected under the whistleblower provisions of applicable law, or from
making any other truthful disclosures required by applicable law, regulation, or order of a court or governmental agency.

 

7.       The
Participant acknowledges and agrees that: (a) the Company’s Confidential Information is of great competitive importance and
commercial value to the Company; (b) the purpose of the covenants set forth in this Exhibit A (the
 “Covenants”) is to protect the Company’s Confidential Information as well as its goodwill, trade
secrets and other Confidential Information of the Company and its affiliates; (c) improper use or disclosure by Participant is
likely to result in unfair or unlawful competitive activity; (d) because of the nature of the business in which the Company and its
affiliates are engaged and because of the nature of the Confidential Information to which the Participant has or will have access,
it would be impractical and excessively difficult to determine the actual damages of the Company and its affiliates in the event the
Participant breached any such covenants; and (e) remedies at law (such as monetary damages) for any breach of the
Participant’s obligations under the Covenants would be inadequate. The Participant therefore agrees and consents that if the
Participant commits any breach of a Covenant, the Company shall have the right (in addition to, and not in lieu of, any other right
or remedy that may be available to it) to temporary and permanent injunctive relief from a court of competent jurisdiction, without
posting any bond or other security and without the necessity of proof of actual damage.

 

    2

     

    

 

The parties expressly represent
that the Covenants are reasonable in all respects and are necessary to protect the legitimate business interests of the Company and its
affiliates. The parties further acknowledge and agree that the Company and its affiliates conduct the Business on a worldwide basis and
the Participant will have Confidential Information regarding the business conducted by the Company and its affiliates in each location
where it is conducted and the Participant will be materially associated with the Company’s and its affiliates’ goodwill. The
Participant expressly acknowledges and agrees that any violation of the Covenants would inevitably cause the Participant to disclose Confidential
Information of the Company and its affiliates.

 

If any portion of the Covenants
is hereafter determined to be invalid or unenforceable in any respect, such determination shall not affect the remainder thereof, which
shall be given the maximum effect possible and shall be fully enforced, without regard to the invalid portions. In particular, without
limiting the generality of the foregoing, if the covenants set forth in this Exhibit A are found by a court or an arbitrator to be unreasonable,
the Participant and the Company agree that the maximum period, scope or geographical area that is found to be reasonable shall be substituted
for the stated period, scope or area, and that the court or arbitrator shall revise the restrictions contained herein to cover the maximum
period, scope and area permitted by law. If any of the Covenants are determined to be wholly or partially unenforceable in any jurisdiction,
such determination shall not be a bar to or in any way diminish the Company’s right to enforce any such covenant in any other jurisdiction.

 

8.        In
the event that Participant terminates for Good Reason or the Company terminates the Participant’s employment for reasons other than
(a) Cause or (b) the Participant’s death or Disability, the Company shall, subject to the execution of the Release (as defined in
7(c) of the Plan), pay the following amounts to the Participant:

 

(a) Subject to Participant’s
execution of the Release, a lump sum cash payment in an amount equal to 1.5 times the sum of (A) the Participant’s Base Salary and
(B) the Participant’s Target Annual Bonus amount for the year immediately preceding the year of the Participant’s termination
(or, if the Participant did not have a Target Annual Bonus opportunity for such preceding year, the Target Annual Bonus amount for the
year of the Participant’s termination);

 

(b) an amount
equal to the cost of 18 months of continuation coverage premiums for medical coverage for the Participant and his or her eligible
dependents (to the extent such dependents are covered under the Company’s group health plan immediately prior to the date of
termination) under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended, (“COBRA”) at the subsidized
rates that active employees pay to effectuate similar coverage; and

 

    3

     

    

 

(c) Subject to Participant’s
execution of the Release, the payments and benefits provided for in Section 4(a)(ii) and Section 4(a)(iii) of the Plan in the same form
as provided for therein;

 

9.       In
the event a Change of Control (as defined in the LTIP) occurs and Participant terminates for Good Reason during a Change of Control Period,
as defined below, or the Company terminates the Participant’s employment for reasons other than (a) Cause or (b) the Participant’s
death or Disability during a Change of Control Period, the Company shall, subject to the execution of the Release (as defined in 7(c)
of the Plan), pay the following amounts to the Participant:

 

(a) Subject to Participant’s
execution of the Release, a one-time payment of 2.5 times the sum of Participant’s Base Salary plus Target Annual Bonus (in each
case, as then in effect), which shall be paid in a lump-sum on the first administratively feasible payroll date following the date the
Release becomes binding; and

 

(b) Subject to Participant’s
execution of the Release, the payments and benefits provided for in Section 8(b) and 8(c) of this Agreement in the same form as provided
for herein;

 

For purposes of this Participation Agreement,
 “Change of Control Period” means the period commencing on the date on which a Change of Control occurs and ending on the first
anniversary of the date on which a Change of Control occurs.

 

    4Exhibit 4.1

  

   

  

  WARRANT AGREEMENT

   

  between

   

  Sculptor Acquisition Corp I and

   

  CONTINENTAL STOCK TRANSFER & TRUST COMPANY

   

  Dated December 8, 2021

   

  THIS WARRANT AGREEMENT (this “Agreement”), dated December 8, 2021, is by and between Sculptor Acquisition Corp I, a Cayman Islands exempted company (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation, as warrant agent (in such capacity, the “Warrant Agent”).

   

  WHEREAS, it is proposed that the Company enter into that certain Private Placement Warrants Purchase Agreement, with Sculptor Acquisition Sponsor I, a Cayman Islands limited liability company (the “Sponsor”), pursuant to which the Sponsor will purchase an aggregate of 10,000,000 warrants (or up to an aggregate of 11,200,000 warrants if the underwriters in the Offering (defined below) exercise their Over-allotment Option (as
    defined below) in full) simultaneously with the closing of the Offering (and the closing of the Over-allotment Option, if applicable), bearing the legend set forth in Exhibit B hereto (the “Private
      Placement Warrants”) at a purchase price of $1.00 per Private Placement Warrant. Each Private Placement Warrant entitles the holder thereof to purchase one Ordinary Share (as defined below) at a price of $11.50 per share, subject to adjustment
    as described herein; and

   

  WHEREAS, in order to finance the Company’s transaction costs in connection with an intended initial merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination, involving the Company and one or more
    businesses or entities (a “Business Combination”), the Sponsor or an affiliate of the Sponsor or certain of the Company’s officers and directors may, but are not obligated to, loan the Company
    funds as the Company may require, of which up to $2,000,000 of such loans may be convertible into up to an additional 2,000,000 Private Placement Warrants at a price of $1.00 per Private Placement Warrant (the “Working Capital Warrants”); and

  

  

  WHEREAS, in order to extend the period of time to consummate the Business Combination by an additional three months, the Sponsor (or its designees) must deposit into the trust account funds equal to one percent (1.0%) of the gross proceeds of the
    offering ($2,000,000 or $2,300,000 if the over-allotment option is exercised in full), for each of up to three of such three-month extensions, up to a total of $6,000,000 (or $6,900,000 if the underwriters’ over- allotment option is exercised in full),
    in exchange for a non-interest bearing, unsecured promissory note, which may be convertible into warrants at a price of $1.00 per warrant (“Extension Warrants”);

  

  

  WHEREAS, the Company is engaged in an initial public offering (the “Offering”) of units of the Company’s equity securities, each such unit comprised of one Ordinary Share (as defined below)
    and one-half of one Public Warrant (as defined below) (the “Units”) and, in connection therewith, has determined to issue and deliver up to 10,000,000 redeemable warrants (or up to an
    aggregate of 11,500,000 redeemable warrants if the underwriters in the Offering exercise their Over-allotment Option in full) to public investors in the Offering (the “Public Warrants” and,
    together with the Private Placement Warrants, Working Capital Warrants and Extension Warrants, the “Warrants”). Each whole Warrant entitles the holder thereof to purchase one Class A ordinary
    share of the Company, with a par or nominal value of $0.0001 per share (“Ordinary Shares”), for $11.50 per share, subject to adjustment as described herein. Only whole Warrants are
    exercisable. A holder of the Public Warrants will not be able to exercise any fraction of a Warrant; and

  

  

  
    
      

  

  WHEREAS, the Company has filed with the Securities and Exchange Commission (the “Commission”) registration statement on Form S-1, as amended, File No. 333-260302, and a prospectus (the “Prospectus”), for the registration, under the Securities Act of 1933, as amended (the “Securities Act”), of the Units, the Public
    Warrants and the Ordinary Shares included in the Units; and

   

  WHEREAS, the Company desires the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing to so act, in connection with the issuance, registration, transfer, exchange, redemption and exercise of
    the Warrants; and

   

  WHEREAS, the Company desires to provide for the form and provisions of the Warrants, the terms upon which they shall be issued and exercised, and the respective rights, limitation of rights, and immunities of the Company, the Warrant Agent and the
    holders of the Warrants; and

  

  

  WHEREAS, all acts and things have been done and performed which are necessary to make the Warrants, when executed on behalf of the Company and countersigned by or on behalf of the Warrant Agent (if a physical certificate is issued), as provided
    herein, the valid, binding and legal obligations of the Company, and to authorize the execution and delivery of this Agreement.

  

  

  NOW, THEREFORE, in consideration of the mutual agreements herein contained, the parties hereto agree as follows:

  

  

  1. Appointment of Warrant Agent. The Company hereby appoints the Warrant Agent to act as agent for the Company for the Warrants, and the Warrant Agent hereby accepts such appointment and agrees to perform the same in accordance with the
    terms and conditions set forth in this Agreement.

  

  

  
    2. Warrants.

  

   

  
    2.1. Form of Warrant. Each Warrant shall initially be issued in registered form only.

  

   

  2.2. Effect of Countersignature. If a physical certificate is issued, unless and until countersigned by the Warrant Agent pursuant to this Agreement, a certificated Warrant shall be invalid and of no effect and may not be exercised by the
    holder thereof.

  

  

  
    2.3. Registration.

  

   

  2.3.1. Warrant Register. The Warrant Agent shall maintain books (the “Warrant Register”), for the registration of original issuance and the registration of transfer of the Warrants.
    Upon the initial issuance of the Warrants in book- entry form, the Warrant Agent shall issue and register the Warrants in the names of the respective holders thereof in such denominations and otherwise in accordance with instructions delivered to the
    Warrant Agent by the Company. Ownership of beneficial interests in the Public Warrants shall be shown on, and the transfer of such ownership shall be effected through, records maintained by institutions that have accounts with The Depository Trust
    Company (the “Depositary”) (each such institution, with respect to a Warrant in its account, a “Participant”).

   

  If the Depositary subsequently ceases to make its book-entry settlement system available for the Public Warrants, the Company may instruct the Warrant Agent regarding making other arrangements for book-entry settlement. In the event that the Public
    Warrants are not eligible for, or it is no longer necessary to have the Public Warrants available in, book-entry form, the Warrant Agent shall provide written instructions to the Depositary to deliver to the Warrant Agent for cancellation each
    book-entry Public Warrant, and the Company shall instruct the Warrant Agent to deliver to the Depositary definitive certificates in physical form evidencing such Warrants (“Definitive Warrant
      Certificates”) which shall be in the form annexed hereto as Exhibit A.

   

  Physical certificates, if issued, shall be signed by, or bear the facsimile signature of, the Chairman of the Board, Chief Executive Officer, Chief Financial Officer or other principal officer of the Company. In the event the person whose facsimile
    signature has been placed upon any Warrant shall have ceased to serve in the capacity in which such person signed the Warrant before such Warrant is issued, it may be issued with the same effect as if he or she had not ceased to be such at the date of
    issuance. 

   

  
    
      

  

  2.3.2. Registered Holder. Prior to due presentment for registration of transfer of any Warrant, the Company and the Warrant Agent may deem and treat the person in whose name such Warrant is registered in the Warrant Register (the “Registered Holder”) as the absolute owner of such Warrant and of each Warrant represented thereby (notwithstanding any notation of ownership or other writing on any physical certificate made by
    anyone other than the Company or the Warrant Agent), for the purpose of any exercise thereof, and for all other purposes, and neither the Company nor the Warrant Agent shall be affected by any notice to the contrary.

   

  2.4. Detachability of Warrants. The Ordinary Shares and Public Warrants comprising the Units shall begin separate trading on the 52nd day following the date of the Prospectus or, if such 52nd day is not on a day, other than a Saturday,
    Sunday or federal holiday, on which banks in New York City are generally open for normal business (a “Business Day”), then on the immediately succeeding Business Day following such date, or
    earlier (the “Detachment Date”) with the consent of Goldman Sachs & Co. LLC, but in no event shall the Ordinary Shares and the Public Warrants comprising the Units be separately traded
    until (A) the Company has filed (i) a Current Report on Form 8-K with the Commission containing an audited balance sheet reflecting the receipt by the Company of the gross proceeds of the Offering, including the proceeds then received by the Company
    from the exercise by the underwriters of their right to purchase additional Units in the Offering (the “Over-allotment Option”), if the Over- allotment Option is exercised prior to the filing
    of the Current Report on Form 8-K, and (ii) a second or amended Current Report on Form 8-K to provide updated financial information to reflect the exercise of the underwriters’ Over-allotment Option, if the Over-allotment Option is exercised following
    the initial filing of such Current Report on Form 8-K, and (B) the Company issues a press release announcing when such separate trading shall begin.

  

  

  2.5. Fractional Warrants. The Company shall not issue fractional Warrants other than as part of the Units, each of which is comprised of one Ordinary Share and a fraction of one whole Public Warrant. If, upon the detachment of Public
    Warrants from the Units or otherwise, a holder of Warrants would be entitled to receive a fractional Warrant, the Company shall round down to the nearest whole number the number of Warrants to be issued to such holder.

   

  
    2.6. Private Placement Warrants, Working Capital Warrants and Extension Warrants.

  

   

  2.6.1 The Private Placement Warrants, the Working Capital Warrants and the Extension Warrants shall be identical to the Public Warrants, except that so long as they are held by the Sponsor or any of its Permitted
    Transferees (as defined below) the Private Placement Warrants, the Working Capital Warrants and the Extension Warrants: (i) may be exercised for cash or on a “cashless basis,” pursuant to subsection 3.3.1(c) hereof, (ii) including the Ordinary
    Shares issuable upon exercise of the Private Placement Warrants, the Working Capital Warrants or the Extension Warrants, may not be transferred, assigned or sold until thirty (30) days after the completion by the Company of an initial Business
    Combination, and (iii) shall not be redeemable by the Company pursuant to Section 6.1 or Section 6.2 hereof; provided, however, that in the case of (ii), the Private Placement Warrants, the Working Capital Warrants and
    the Extension Warrants and any Ordinary Shares issued upon exercise of the Private Placement Warrants, the Working Capital Warrants and the Extension Warrants may be transferred by the holders thereof:

  

  

  (a) to the Company’s officers or directors, any affiliates or family members of any of the Company’s officers or directors, any direct or indirect members or managers of the Sponsor or their affiliates, any affiliates of the Sponsor, including to
    funds affiliated with Sculptor Capital Management, Inc. (“Sculptor”), and to limited partners of funds affiliated with Sculptor, or any employees of such affiliates;

  

  

  (b) in the case of an individual, by gift to a member of one of the individual’s immediate family or to a trust, the beneficiary of which is a member of the individual’s immediate family, an affiliate of such person or to a charitable organization;

  

  

  
    (c) in the case of an individual, by virtue of laws of descent and distribution upon death of the individual;

  

   

  
    (d) in the case of an individual, pursuant to a qualified domestic relations order;

  

  

  

  
    
      

  

  (e) by private sales or transfers made in connection with the consummation of the Company’s Business Combination at prices no greater than the price at which the Private Placement Warrants, the Working Capital Warrants or the Extension Warrants or
    Ordinary Shares, as applicable, were originally purchased;

   

  
    (f) by virtue of the Sponsor’s organizational documents upon liquidation or dissolution of the Sponsor;

  

   

  (g) to the Company for no value for cancellation in connection with the consummation of our initial Business Combination;

  

  

  
    (h) in the event of the Company’s liquidation prior to the completion of its initial Business Combination; or

  

   

  (i) in the event of the Company’s completion of a liquidation, merger, share exchange or other similar transaction which results in all of the public shareholders having the right to exchange their Ordinary Shares for cash, securities or other
    property subsequent to the completion of the Company’s initial Business Combination;

  

  

  provided, however, that, in the case of clauses (a) through (i), these permitted
      transferees (the “Permitted Transferees”) must enter into a written agreement with the Company agreeing to be bound by the transfer restrictions in this Agreement.

  

  

  
    3. Terms and Exercise of Warrants.

  

   

  3.1. Exercise Price. Each whole Warrant shall entitle the Registered Holder thereof, subject to the provisions of such Warrant and of this Agreement, to purchase from the Company the number of Ordinary Shares stated therein, at the price of
    $11.50 per share, subject to the adjustments provided in Section 4 hereof and in the last sentence of this Section 3.1. The term “Exercise Price” as used in this Agreement shall
    mean the price per share (including in cash or by payment of Warrants pursuant to a “cashless exercise,” to the extent permitted hereunder) described in the prior sentence at which Ordinary Shares may be purchased at the time a Warrant is exercised.
    The Company in its sole discretion may lower the Exercise Price at any time prior to the Expiration Date (as defined below) for a period of not less than fifteen Business Days (unless otherwise required by the Commission, any national securities
    exchange on which the Warrants are listed or applicable law); provided that the Company shall provide at least three Business Days’ prior written notice of such reduction to Registered Holders of the Warrants; and, provided further, that any such
    reduction shall be identical among all of the Warrants.

   

  3.2. Duration of Warrants. A Warrant may be exercised only during the period (the “Exercise Period”) (A) commencing on the later of: (i) the date that is thirty (30) days after the
    first date on which the Company completes an initial Business Combination, and (ii) the date that is twelve (12) months from the date of the closing of the Offering, and (B) terminating at the earliest to occur of (x) 5:00 p.m., New York City time on
    the date that is five (5) years after the date on which the Company completes its initial Business Combination, (y) the liquidation of the Company in accordance with the Company’s amended and restated memorandum and articles of association, as amended
    and/or restated from time to time, if the Company fails to complete a Business Combination, and (z) other than with respect to the Private Placement Warrants, the Working Capital Warrants and the Extension Warrants then held by the Sponsor or its
    Permitted Transferees, 5:00 p.m., New York City time on the Redemption Date (as defined below) as provided in Section 6.3 hereof (the “Expiration Date”); provided, however,
    that the exercise of any Warrant shall be subject to the satisfaction of any applicable conditions, as set forth in subsection 3.3.2 below, with respect to an effective registration statement or a valid exemption therefrom being available.
    Except with respect to the right to receive the Redemption Price (as defined below) (other than with respect to a Private Placement Warrant, a Working Capital Warrant or an Extension Warrant then held by the Sponsor or its Permitted Transferees) in the
    event of a redemption (as set forth in Section 6 hereof), each Warrant (other than a Private Placement Warrant, a Working Capital Warrant or an Extension Warrant then held by the Sponsor or its Permitted Transferees in the event of a
    redemption) not exercised on or before the Expiration Date shall become void, and all rights thereunder and all rights in respect thereof under this Agreement shall cease at 5:00 p.m. New York City time on the Expiration Date. The Company in its sole
    discretion may extend the duration of the Warrants by delaying the Expiration Date; provided that the Company shall provide at least twenty (20) days prior written notice of any such extension to Registered Holders of the Warrants and, provided
      further that any such extension shall be identical in duration among all the Warrants.

  

  

  
    
      

  

  
    3.3. Exercise of Warrants.

  

   

  3.3.1. Payment. Subject to the provisions of the Warrant and this Agreement, a Warrant may be exercised by the Registered Holder thereof by delivering to the Warrant Agent at its corporate trust department (i) the Definitive Warrant
    Certificate evidencing the Warrants to be exercised, or, in the case of a Warrant represented by a book- entry, the Warrants to be exercised (the “Book-Entry Warrants”) on the records of the
    Depositary to an account of the Warrant Agent at the Depositary designated for such purposes in writing by the Warrant Agent to the Depositary from time to time, (ii) an election to purchase (“Election
      to Purchase”) any Ordinary Shares pursuant to the exercise of a Warrant, properly completed and executed by the Registered Holder on the reverse of the Definitive Warrant Certificate or, in the case of a Book-Entry Warrant, properly delivered
    by the Participant in accordance with the Depositary’s procedures, and (iii) the payment in full of the Exercise Price for each Ordinary Share as to which the Warrant is exercised and any and all applicable taxes due in connection with the exercise of
    the Warrant, the exchange of the Warrant for the Ordinary Shares and the issuance of such Ordinary Shares, as follows:

   

  (a) in lawful money of the United States, in good certified check or good bank draft payable to the order of the Warrant Agent;

  

  

  
    (b) [Reserved];

  

   

  (c) with respect to any Private Placement Warrant, Working Capital Warrant or Extension Warrant, so long as such Private Placement Warrant, Working Capital Warrant or Extension Warrant is held by the Sponsor or a Permitted Transferee, by
    surrendering the Warrants for that number of Ordinary Shares equal to the quotient obtained by dividing (x) the product of the number of Ordinary Shares underlying the Warrants, multiplied by the excess of the “Sponsor Fair Market Value” (as defined in this subsection 3.3.1(c)) less the Exercise Price by (y) the Sponsor Fair Market Value. Solely for purposes of this subsection 3.3.1(c), the “Sponsor Fair Market Value” shall mean the average last reported sale price of the Ordinary Shares for the ten (10) trading days ending on the third (3rd) trading day prior to the date on which
    notice of exercise of the Private Placement Warrant, Working Capital Warrant or Extension Warrant is sent to the Warrant Agent;

  

  

  
    (d) as provided in Section 6.2 hereof with respect to a Make-Whole Exercise; or

  

   

  
    (e) as provided in Section 7.4 hereof.

  

   

  3.3.2. Issuance of Ordinary Shares on Exercise. As soon as practicable after the exercise of any Warrant and the clearance of the funds in payment of the Exercise Price (if payment is pursuant to subsection 3.3.1(a)), the Company
    shall issue to the Registered Holder of such Warrant a book-entry position or certificate, as applicable, for the number of Ordinary Shares to which he, she or it is entitled, registered in such name or names as may be directed by him, her or it on the
    register of members of the Company, and if such Warrant shall not have been exercised in full, a new book-entry position or countersigned Warrant, as applicable, for the number of shares as to which such Warrant shall not have been exercised. If fewer
    than all the Warrants evidenced by a book entry position are exercised, a notation shall be made to the records maintained by the Depositary, its nominee for each book entry position, or the applicable institution with an account at the Depositary, as
    appropriate, evidencing the balance of the Warrants remaining after such exercise. Notwithstanding the foregoing, in no event will the Company be required to net cash settle the Warrant exercise. Notwithstanding the foregoing, the Company shall not be
    obligated to deliver any Ordinary Shares pursuant to the exercise of a Warrant and shall have no obligation to settle such Warrant exercise unless a registration statement under the Securities Act with respect to the Ordinary Shares underlying the
    Public Warrants is then effective and a prospectus relating thereto is current, subject to the Company’s satisfying its obligations under Section 7.4 or a valid exemption from registration is available. No Warrant shall be exercisable and the
    Company shall not be obligated to issue Ordinary Shares upon exercise of a Warrant unless the Ordinary Shares issuable upon such Warrant exercise have been registered, qualified or deemed to be exempt from registration or qualification under the
    securities laws of the state of residence of the Registered Holder of the Warrants. Subject to Section 4.6 of this Agreement, a Registered Holder of Warrants may exercise its Warrants only for a whole number of Ordinary Shares. The Company may
    require holders of Public Warrants to settle the Warrant on a “cashless basis” pursuant to Section 7.4. If, by reason of any exercise of Warrants on a “cashless basis”, the holder of any Warrant would be entitled, upon the exercise of such
    Warrant, to receive a fractional interest in an Ordinary Share, the Company shall round down to the nearest whole number, the number of Ordinary Shares to be issued to such holder. 

   

  
    
      

  

  3.3.3. Valid Issuance. All Ordinary Shares issued upon the proper exercise of a Warrant in conformity with this Agreement shall be validly issued, fully paid and nonassessable.

   

  3.3.4. Date of Issuance. Each person in whose name any book-entry position or certificate, as applicable, for Ordinary Shares is issued and who is registered in the register of members of the Company shall for all purposes be deemed to have
    become the holder of record of such Ordinary Shares on the date on which the Warrant, or book- entry position representing such Warrant, was surrendered and payment of the Exercise Price was made, irrespective of the date of delivery of such
    certificate in the case of a certificated Warrant, except that, if the date of such surrender and payment is a date when the register of members of the Company or book-entry system of the Warrant Agent are closed, such person shall be deemed to have
    become the holder of such shares at the close of business on the next succeeding date on which the share transfer books or book-entry system are open.

  

  

  3.3.5. Maximum Percentage. A holder of a Warrant may notify the Company in writing in the event it elects to be subject to the provisions contained in this subsection 3.3.5; however, no holder of a Warrant shall be subject to
    this subsection 3.3.5 unless he, she or it makes such election. If the election is made by a holder, the Warrant Agent shall not affect the exercise of the holder’s Warrant, and such holder shall not have the right to exercise such Warrant, to
    the extent that after giving effect to such exercise, such person (together with such person’s affiliates), to the Warrant Agent’s actual knowledge, would beneficially own in excess of 9.8% (the “Maximum
      Percentage”) of the Ordinary Shares outstanding immediately after giving effect to such exercise. For purposes of the foregoing sentence, the aggregate number of Ordinary Shares beneficially owned by such person and its affiliates shall
    include the number of Ordinary Shares issuable upon exercise of the Warrant with respect to which the determination of such sentence is being made, but shall exclude Ordinary Shares that would be issuable upon (x) exercise of the remaining, unexercised
    portion of the Warrant beneficially owned by such person and its affiliates and (y) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company beneficially owned by such person and its affiliates (including,
    without limitation, any convertible notes or convertible preferred shares or warrants) subject to a limitation on conversion or exercise analogous to the limitation contained herein. Except as set forth in the preceding sentence, for purposes of this
    paragraph, beneficial ownership shall be calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). For purposes of the Warrant, in
    determining the number of outstanding Ordinary Shares, the holder may rely on the number of outstanding Ordinary Shares as reflected in (1) the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, Current Report on Form 8-K
    or other public filing with the Commission as the case may be, (2) a more recent public announcement by the Company or (3) any other notice by the Company or Continental Stock Transfer & Trust Company, as transfer agent (in such capacity, the “Transfer Agent”), setting forth the number of Ordinary Shares outstanding. For any reason at any time, upon the written request of the holder of the Warrant, the Company shall, within two (2)
    Business Days, confirm orally and in writing to such holder the number of Ordinary Shares then outstanding. In any case, the number of issued and outstanding Ordinary Shares shall be determined after giving effect to the conversion or exercise of
    equity securities of the Company by the holder and its affiliates since the date as of which such number of issued and outstanding Ordinary Shares was reported. By written notice to the Company, the holder of a Warrant may from time to time increase or
    decrease the Maximum Percentage applicable to such holder to any other percentage specified in such notice; provided, however, that any such increase shall not be effective until the sixty-first (61st) day after such notice is delivered
    to the Company.

   

  
    
      

  

  
    4. Adjustments.

  

   

  
    4.1. Share Capitalizations.

  

   

  4.1.1. Sub-Divisions. If after the date hereof, and subject to the provisions of Section 4.6 below, the number of issued and outstanding Ordinary Shares is increased by a capitalization or share dividend of Ordinary Shares, or by a
    sub-division of Ordinary Shares or other similar event, then, on the effective date of such share capitalization, sub- division or similar event, the number of Ordinary Shares issuable on exercise of each Warrant shall be increased in proportion to
    such increase in the issued and outstanding Ordinary Shares. A rights offering made to all or substantially all holders of Ordinary Shares entitling holders to purchase Ordinary Shares at a price less than the

   

  “Historical Fair Market Value” (as defined below) shall be deemed a capitalization of a number of Ordinary Shares equal to the product of (i) the number of Ordinary Shares actually sold in such rights offering (or issuable under any other equity
    securities sold in such rights offering that are convertible into or exercisable for the Ordinary Shares) multiplied by (ii) one (1) minus the quotient of (x) the price per Ordinary Share paid in such rights offering divided by (y) the Historical Fair
    Market Value. For purposes of this subsection 4.1.1, (i) if the rights offering is for securities convertible into or exercisable for Ordinary Shares, in determining the price payable for Ordinary Shares, there shall be taken into account any
    consideration received for such rights, as well as any additional amount payable upon exercise or conversion and (ii) “Historical Fair Market Value” means the volume weighted average price of
    the Ordinary Shares during the ten (10) trading day period ending on the trading day prior to the first date on which the Ordinary Shares trade on the applicable exchange or in the applicable market, regular way, without the right to receive such
    rights. No Ordinary Shares shall be issued at less than their par value.

  

  

  4.1.2. Extraordinary Dividends. If the Company, at any time while the Warrants are outstanding and unexpired, pays to all or substantially all of the holders of the Ordinary Shares a dividend or makes a distribution in cash, securities or
    other assets on account of such Ordinary Shares (or other shares into which the Warrants are convertible), other than (a) as described in subsection 4.1.1 above, (b) Ordinary Cash Dividends (as defined below), (c) to satisfy the redemption
    rights of the holders of the Ordinary Shares in connection with a proposed initial Business Combination, (d) to satisfy the redemption rights of the holders of the Ordinary Shares in connection with a shareholder vote to amend the Company’s amended and
    restated memorandum and articles of association (i) to modify the substance or timing of the Company’s obligation to provide holders of Ordinary Shares the right to have their shares redeemed in connection with the Company’s initial Business
    Combination or to redeem 100% of the Company’s public shares included in the Units sold in the Offering (the “Public Shares”) if it does not complete its initial Business Combination within
    the time period required by the Company’s amended and restated memorandum and articles of association, as amended and/or restated from time to time, or (ii) with respect to any other provision relating to the rights of holders of Ordinary Shares, (e)
    as a result of the redemption of Public Shares by the Company if a proposed initial Business Combination is presented to the public shareholders of the Company for approval or (f) in connection with the redemption of Public Shares upon the failure of
    the Company to complete its initial Business Combination and any subsequent distribution of its assets upon its liquidation (any such non-excluded event being referred to herein as an “Extraordinary
      Dividend”), then the Exercise Price shall be decreased, effective immediately after the effective date of such Extraordinary Dividend, by the amount of cash and/or the fair market value (as determined by the Company’s board of directors (the “Board”), in good faith) of any securities or other assets paid on each Ordinary Share in respect of such Extraordinary Dividend. For purposes of this subsection 4.1.2, “Ordinary Cash Dividends” means any cash dividend or cash distribution which, when combined on a per share basis, with the per share amounts of all other cash dividends and cash distributions paid
    on the Ordinary Shares during the 365-day period ending on the date of declaration of such dividend or distribution to the extent it does not exceed $0.50 (which amount shall be adjusted to appropriately reflect any of the events referred to in other
    subsections of this Section 4 and excluding cash dividends or cash distributions that resulted in an adjustment to the Exercise Price or to the number of Ordinary Shares issuable on exercise of each Warrant). 

   

  4.2. Aggregation of Shares. If after the date hereof, and subject to the provisions of Section 4.6 hereof, the number of issued and outstanding Ordinary Shares is decreased by a consolidation, combination, reverse share split or
    reclassification of Ordinary Shares or other similar event, then, on the effective date of such consolidation, combination, reverse share split, reclassification or similar event, the number of Ordinary Shares issuable on exercise of each Warrant shall
    be decreased in proportion to such decrease in issued and outstanding Ordinary Shares.

   

  4.3. Adjustments in Exercise Price. Whenever the number of Ordinary Shares purchasable upon the exercise of the Warrants is adjusted, as provided in subsection 4.1.1 or Section 4.2 above, the Exercise Price shall be adjusted
    (to the nearest cent) by multiplying such Exercise Price immediately prior to such adjustment by a fraction (x) the numerator of which shall be the number of Ordinary Shares purchasable upon the exercise of the Warrants immediately prior to such
    adjustment, and (y) the denominator of which shall be the number of Ordinary Shares so purchasable immediately thereafter.

   

  
    
      

  

  4.4.  Raising of the Capital in Connection with the Initial Business Combination. If (x) the Company issues additional Ordinary Shares or equity-linked securities for capital raising purposes in connection with the closing of its initial
    Business Combination at an issue price or effective issue price of less than $9.20 per Ordinary Share (with such issue price or effective issue price to be determined in good faith by the Board and, in the case of any such issuance to the Sponsor or
    its affiliates, without taking into account any Class B ordinary shares, with a par or nominal value of $0.0001 per share, of the Company (the “Class B Ordinary Shares”) held by the Sponsor or
    such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds,
    and interest thereon, available for the funding of the Company’s initial Business Combination on the date of the completion of the Company’s initial Business Combination (net of redemptions), and (z) the volume-weighted average trading price of
    Ordinary Shares during the twenty (20) trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the “Market Value”) is below $9.20 per share, the Exercise Price shall
    be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price described in Section 6.1 shall be adjusted (to the nearest cent) to be equal to
    180% of the higher of the Market Value and the Newly Issued Price and the $10.00 per share redemption trigger price described in Section 6.2 shall be adjusted (to the nearest cent) to be equal to the higher of the Market Value and the Newly Issued
    Price.

  

  

  4.5. Replacement of Securities upon Reorganization, etc. In case of any reclassification or reorganization of the issued and outstanding Ordinary Shares (other than a change under Section 4.1 or Section 4.2 hereof or that
    solely affects the par value of such Ordinary Shares), or in the case of any merger or consolidation of the Company with or into another corporation (other than a consolidation or merger in which the Company is the continuing corporation and that does
    not result in any reclassification or reorganization of the issued and outstanding Ordinary Shares), or in the case of any sale or conveyance to another corporation or entity of the assets or other property of the Company as an entirety or
    substantially as an entirety in connection with which the Company is dissolved, the holders of the Warrants shall thereafter have the right to purchase and receive, upon the basis and upon the terms and conditions specified in the Warrants and in lieu
    of the Ordinary Shares of the Company immediately theretofore purchasable and receivable upon the exercise of the rights represented thereby, the kind and amount of shares or stock or other securities or property (including cash) receivable upon such
    reclassification, reorganization, merger or consolidation, or upon a dissolution following any such sale or transfer, that the holder of the Warrants would have received if such holder had exercised his, her or its Warrant(s) immediately prior to such
    event (the “Alternative Issuance”); provided, however, that (i) if the holders of the Ordinary Shares were entitled to exercise a right of election as to the kind or amount of
    securities, cash or other assets receivable upon such consolidation or merger, then the kind and amount of securities, cash or other assets constituting the Alternative Issuance for which each Warrant shall become exercisable shall be deemed to be the
    weighted average of the kind and amount received per share by the holders of the Ordinary Shares in such consolidation or merger that affirmatively make such election, and (ii) if a tender, exchange or redemption offer shall have been made to and
    accepted by the holders of the Ordinary Shares (other than a tender, exchange or redemption offer made by the Company in connection with redemption rights held by shareholders of the Company as provided for in the Company’s amended and restated
    memorandum and articles of association or as a result of the redemption of Ordinary Shares by the Company if a proposed initial Business Combination is presented to the shareholders of the Company for approval) under circumstances in which, upon
    completion of such tender, exchange or redemption offer, the maker thereof, together with members of any group (within the meaning of Rule 13d-5(b)(1) under the Exchange Act (or any successor rule)) of which such maker is a part, and together with any
    affiliate or associate of such maker (within the meaning of Rule 12b-2 under the Exchange Act (or any successor rule)) and any members of any such group of which any such affiliate or associate is a part, own beneficially (within the meaning of Rule
    13d-3 under the Exchange Act (or any successor rule)) more than 50% of the issued and outstanding Ordinary Shares, the holder of a Warrant shall be entitled to receive as the Alternative Issuance, the highest amount of cash, securities or other
    property to which such holder would actually have been entitled as a shareholder if such Warrant holder had exercised the Warrant prior to the expiration of such tender, exchange or redemption offer, accepted such offer and all of the Ordinary Shares
    held by such holder had been purchased pursuant to such tender, exchange or redemption offer, subject to adjustments (from and after the consummation of such tender or exchange offer) as nearly equivalent as possible to the adjustments provided for in
    this Section 4; provided further that if less than 70% of the consideration receivable by the holders of the Ordinary Shares in the applicable event is payable in the form of capital stock or shares in the successor entity that is
    listed for trading on a national securities exchange or is quoted in an established over-the-counter market, or is to be so listed for trading or quoted immediately following such event, and if the Registered Holder properly exercises the Warrant
    within thirty (30) days following the public disclosure of the consummation of such applicable event by the Company pursuant to a Current Report on Form 8-K filed with the Commission, the Exercise Price shall be reduced by an amount (in dollars) equal
    to the difference of (i) the Exercise Price in effect prior to such reduction minus (ii) (A) the Per Share Consideration (as defined below) (but in no event less than zero) minus (B) the Black-Scholes Warrant Value (as defined below). The “Black-Scholes Warrant Value” means the value of a Warrant immediately prior to the consummation of the applicable event based on the Black-Scholes Warrant Model for a Capped American Call on
    Bloomberg Financial Markets (assuming zero dividends) (“Bloomberg”). For purposes of calculating such amount, (i) Section 6 of this Agreement shall be taken into account, (ii) the price
    of each Ordinary Share shall be the volume weighted average price of the Ordinary Shares during the ten (10) trading day period ending on the trading day prior to the effective date of the applicable event, (iii) the assumed volatility shall be the 90
    day volatility obtained from the HVT function on Bloomberg determined as of the trading day immediately prior to the day of the announcement of the applicable event and (iv) the assumed risk-free interest rate shall correspond to the U.S. Treasury rate
    for a period equal to the remaining term of the Warrant. “Per Share Consideration” means (i) if the consideration paid to holders of the Ordinary Shares consists exclusively of cash, the
    amount of such cash per Ordinary Share, and (ii) in all other cases, the volume weighted average price of the Ordinary Shares during the ten (10) trading day period ending on the trading day prior to the effective date of the applicable event. If any
    reclassification or reorganization also results in a change in Ordinary Shares covered by subsection 4.1.1, then such adjustment shall be made pursuant to subsection 4.1.1 or Sections 4.2, 4.3 and this Section 4.4.
    The provisions of this Section 4.4 shall similarly apply to successive reclassifications, reorganizations, mergers or consolidations, sales or other transfers. In no event shall the Exercise Price be reduced to less than the par value per share
    issuable upon exercise of such Warrant.

   

  
    
      

  

  4.6. Notices of Changes in Warrant. Upon every adjustment of the Exercise Price or the number of shares issuable upon exercise of a Warrant, the Company shall give written notice thereof to the Warrant Agent, which notice shall state the
    Exercise Price resulting from such adjustment and the increase or decrease, if any, in the number of shares purchasable at such price upon the exercise of a Warrant, setting forth in reasonable detail the method of calculation and the facts upon which
    such calculation is based. Upon the occurrence of any event specified in Sections 4.1, 4.2, 4.3, 4.4 or 4.5, the Company shall give written notice of the occurrence of such event to each holder of a Warrant, at
    the last address set forth for such holder in the Warrant Register, of the record date or the effective date of the event. Failure to give such notice, or any defect therein, shall not affect the legality or validity of such event.

  

  

  4.7. No Fractional Shares. Notwithstanding any provision contained in this Agreement to the contrary, the Company shall not issue fractional shares upon the exercise of Warrants. If, by reason of any adjustment made pursuant to this
      Section 4, the holder of any Warrant would be entitled, upon the exercise of such Warrant, to receive a fractional interest in a share, the Company shall, upon such exercise, round down to the nearest whole number the number of Ordinary Shares to
    be issued to such holder.

   

  4.8. Form of Warrant. The form of Warrant need not be changed because of any adjustment pursuant to this Section 4, and Warrants issued after such adjustment may state the same Exercise Price and the same number of shares as is
    stated in the Warrants initially issued pursuant to this Agreement; provided, however, that the Company may at any time in its sole discretion make any change in the form of Warrant that the Company may deem appropriate and that does
    not affect the substance thereof, and any Warrant thereafter issued or countersigned, whether in exchange or substitution for an outstanding Warrant or otherwise, may be in the form as so changed.

   

  4.9. Other Events. In case any event shall occur affecting the Company as to which none of the provisions of the preceding subsections of this Section 4 are strictly applicable, but which would require an adjustment to the terms of
    the Warrants in order to (i) avoid an adverse impact on the Warrants and (ii) effectuate the intent and purpose of this Section 4, then, in each such case, the Company shall appoint a firm of independent public accountants, investment banking or
    other appraisal firm of recognized national standing, which shall give its opinion as to whether or not any adjustment to the rights represented by the Warrants is necessary to effectuate the intent and purpose of this Section 4 and, if they
    determine that an adjustment is necessary, the terms of such adjustment, provided, however, that under no circumstances shall the Warrants be adjusted pursuant to this Section 4.9 as a result of any issuance of securities in connection with an initial
    Business Combination. The Company shall adjust the terms of the Warrants in a manner that is consistent with any adjustment recommended in such opinion.

   

  4.10. No Adjustment. For the avoidance of doubt, no adjustment shall be made to the terms of the Warrants solely as a result of an adjustment to the conversion ratio of the Class B Ordinary Shares into Ordinary Shares or the conversion of
    Class B Ordinary Shares into Ordinary Shares, in each case, pursuant to the Company’s amended and restated memorandum and articles of association.

  

  

  
    
      

  

  
    5. Transfer and Exchange of Warrants.

  

   

  5.1. Registration of Transfer. The Warrant Agent shall register the transfer, from time to time, of any outstanding Warrant upon the Warrant Register, upon surrender of such Warrant for transfer, in the case of a certificated Warrant,
    properly endorsed with signatures properly guaranteed and accompanied by appropriate instructions for transfer. Upon any such transfer, a new Warrant representing an equal aggregate number of Warrants shall be issued and the old Warrant shall be
    cancelled by the Warrant Agent. In the case of certificated Warrants, the Warrants so cancelled shall be delivered by the Warrant Agent to the Company from time to time upon request.

   

  5.2. Procedure for Surrender of Warrants. Warrants may be surrendered to the Warrant Agent, together with a written request for exchange or transfer, and thereupon the Warrant Agent shall issue in exchange therefor one or more new Warrants
    as requested by the Registered Holder of the Warrants so surrendered, representing an equal aggregate number of Warrants; provided, however, that except as otherwise provided herein or with respect to any Book-Entry Warrant, each
    Book-Entry Warrant may be transferred only in whole and only to the Depositary, to another nominee of the Depositary, to a successor depository, or to a nominee of a successor depository; provided further, however that in the event that
    a Warrant surrendered for transfer bears a restrictive legend (as in the case of the Private Placement Warrants, Working Capital Warrants and Extension Warrants), the Warrant Agent shall not cancel such Warrant and issue new Warrants in exchange
    thereof until the Warrant Agent has received an opinion of counsel for the Company stating that such transfer may be made and indicating whether the new Warrants must also bear a restrictive legend.

  

  

  5.3. Fractional Warrants. The Warrant Agent shall not be required to effect any registration of transfer or exchange which shall result in the issuance of a warrant certificate or book-entry position for a fraction of a warrant, except as
    part of the Units.

   

  
    5.4. Service Charges. No service charge shall be made for any exchange or registration of transfer of Warrants.

  

   

  5.5.  Warrant Execution and Countersignature. The Warrant Agent is hereby authorized to countersign and to deliver, in accordance with the terms of this Agreement, the Warrants required to be issued pursuant to the provisions of this
      Section 5, and the Company, whenever required by the Warrant Agent, shall supply the Warrant Agent with Warrants duly executed on behalf of the Company for such purpose.

   

  5.6. Transfer of Warrants. Prior to the Detachment Date, the Public Warrants may be transferred or exchanged only together with the Unit in which such Warrant is included, and only for the purpose of effecting, or in conjunction with, a
    transfer or exchange of such Unit. Furthermore, each transfer of a Unit on the register relating to such Units shall operate also to transfer the Warrants included in such Unit. Notwithstanding the foregoing, the provisions of this Section 5.6
    shall have no effect on any transfer of Warrants on and after the Detachment Date.

   

  
    6. Redemption.

  

   

  6.1. Redemption of Warrants When the Price per Ordinary Share Equals or Exceeds $18.00. Subject to Section 6.5 hereof, not less than all of the outstanding Warrants may be redeemed, at the option of the Company, at any time during
    the Exercise Period, at the office of the Warrant Agent, upon notice to the Registered Holders of the Warrants, as described in Section 6.3 below, at a Redemption Price of $0.01 per Warrant, provided that (a) the last reported sale
    price of the Ordinary Shares equals or exceeds $18.00 per share (subject to adjustment in compliance with Section 4 hereof) for any 10 trading days within a 20-day period commencing no earlier than the date the Warrants become exercisable and
    ending on the third trading day prior to the date on which notice of such redemption is sent to the Registered Holders, as described in Section 6.3 below (the “20-day Reference Period”) and (b) there is an effective registration statement
    covering the issuance of the Ordinary Shares issuable upon exercise of the Warrants, and a current prospectus relating thereto, available throughout the 30-day Redemption Period (as defined in Section 6.3 below). 

   

  
    
      

  

  6.2. Redemption of Warrants When the Price per Ordinary Share Equals or Exceeds $10.00. Subject to Section 6.5 hereof, not less than all of the outstanding Warrants may be redeemed, at the option of the Company, at any time during
    the Exercise Period, at the office of the Warrant Agent, upon notice to the Registered Holders of the Warrants, as described in Section 6.3 below, at a Redemption Price of $0.10 per Warrant, provided that the last reported sale price of
    the Ordinary Shares equals or exceeds $10.00 per share (subject to adjustment in compliance with Section 4 hereof) for any 10 trading days within a 20-day Reference Period. During the 30-day Redemption Period in connection with a redemption
    pursuant to this Section 6.2, Registered Holders of the Warrants may elect to exercise their Warrants on a “cashless basis” pursuant to subsection 3.3.1 and receive a number of Ordinary Shares determined by reference to the table below,
    based on the Redemption Date (calculated for purposes of the table as the period to expiration of the Warrants) and the “Redemption Fair Market Value” (as such term is defined in this Section 6.2) (a “Make-Whole Exercise”). Solely for purposes of this Section 6.2, the “Redemption Fair Market Value” shall mean the volume weighted average price of the Ordinary Shares
    for the ten (10) trading days immediately following the date on which notice of redemption pursuant to this Section 6.2 is sent to the Registered Holders. In connection with any redemption pursuant to this Section 6.2, the Company shall
    provide the Registered Holders with the Redemption Fair Market Value no later than one (1) Business Day after the ten (10) trading day period described above ends.

  

  

  	 	

        	
          Redemption Fair Market Value of Ordinary Shares

          (period to expiration of warrants)

        	 
	
          Redemption Date

        	 	
          ≤

          10.00

        	 	 	 	
          

          11.00

        	 	 	 	
          

          12.00

        	 	 	 	
          

          13.00

        	 	 	 	
          

          14.00

        	 	 	 	
          

          15.00

        	 	 	 	
          

          16.00

        	 	 	 	
          

          17.00

        	 	 	
          ≥

          18.00

        	 
	
          60 months

        	 	 	
          0.261

        	 	 	 	
          0.280

        	 	 	 	
          0.297

        	 	 	 	
          0.311

        	 	 	 	
          0.324

        	 	 	 	
          0.337

        	 	 	 	
          0.348

        	 	 	 	
          0.358

        	 	 	 	
          0.361

        	 
	
          57 months

        	 	 	
          0.257

        	 	 	 	
          0.277

        	 	 	 	
          0.294

        	 	 	 	
          0.310

        	 	 	 	
          0.324

        	 	 	 	
          0.337

        	 	 	 	
          0.348

        	 	 	 	
          0.358

        	 	 	 	
          0.361

        	 
	
          54 months

        	 	 	
          0.252

        	 	 	 	
          0.272

        	 	 	 	
          0.291

        	 	 	 	
          0.307

        	 	 	 	
          0.322

        	 	 	 	
          0.335

        	 	 	 	
          0.347

        	 	 	 	
          0.357

        	 	 	 	
          0.361

        	 
	
          51 months

        	 	 	
          0.246

        	 	 	 	
          0.268

        	 	 	 	
          0.287

        	 	 	 	
          0.304

        	 	 	 	
          0.320

        	 	 	 	
          0.333

        	 	 	 	
          0.346

        	 	 	 	
          0.357

        	 	 	 	
          0.361

        	 
	
          48 months

        	 	 	
          0.241

        	 	 	 	
          0.263

        	 	 	 	
          0.283

        	 	 	 	
          0.301

        	 	 	 	
          0.317

        	 	 	 	
          0.332

        	 	 	 	
          0.344

        	 	 	 	
          0.356

        	 	 	 	
          0.361

        	 
	
          45 months

        	 	 	
          0.235

        	 	 	 	
          0.258

        	 	 	 	
          0.279

        	 	 	 	
          0.298

        	 	 	 	
          0.315

        	 	 	 	
          0.330

        	 	 	 	
          0.343

        	 	 	 	
          0.356

        	 	 	 	
          0.361

        	 
	
          42 months

        	 	 	
          0.228

        	 	 	 	
          0.252

        	 	 	 	
          0.274

        	 	 	 	
          0.294

        	 	 	 	
          0.312

        	 	 	 	
          0.328

        	 	 	 	
          0.342

        	 	 	 	
          0.355

        	 	 	 	
          0.361

        	 
	
          39 months

        	 	 	
          0.221

        	 	 	 	
          0.246

        	 	 	 	
          0.269

        	 	 	 	
          0.290

        	 	 	 	
          0.309

        	 	 	 	
          0.325

        	 	 	 	
          0.340

        	 	 	 	
          0.354

        	 	 	 	
          0.361

        	 
	
          36 months

        	 	 	
          0.213

        	 	 	 	
          0.239

        	 	 	 	
          0.263

        	 	 	 	
          0.285

        	 	 	 	
          0.305

        	 	 	 	
          0.323

        	 	 	 	
          0.339

        	 	 	 	
          0.353

        	 	 	 	
          0.361

        	 
	
          33 months

        	 	 	
          0.205

        	 	 	 	
          0.232

        	 	 	 	
          0.257

        	 	 	 	
          0.280

        	 	 	 	
          0.301

        	 	 	 	
          0.320

        	 	 	 	
          0.337

        	 	 	 	
          0.352

        	 	 	 	
          0.361

        	 
	
          30 months

        	 	 	
          0.196

        	 	 	 	
          0.224

        	 	 	 	
          0.250

        	 	 	 	
          0.274

        	 	 	 	
          0.297

        	 	 	 	
          0.316

        	 	 	 	
          0.335

        	 	 	 	
          0.351

        	 	 	 	
          0.361

        	 
	
          27 months

        	 	 	
          0.185

        	 	 	 	
          0.214

        	 	 	 	
          0.242

        	 	 	 	
          0.268

        	 	 	 	
          0.291

        	 	 	 	
          0.313

        	 	 	 	
          0.332

        	 	 	 	
          0.350

        	 	 	 	
          0.361

        	 
	
          24 months

        	 	 	
          0.173

        	 	 	 	
          0.204

        	 	 	 	
          0.233

        	 	 	 	
          0.260

        	 	 	 	
          0.285

        	 	 	 	
          0.308

        	 	 	 	
          0.329

        	 	 	 	
          0.348

        	 	 	 	
          0.361

        	 
	
          21 months

        	 	 	
          0.161

        	 	 	 	
          0.193

        	 	 	 	
          0.223

        	 	 	 	
          0.252

        	 	 	 	
          0.279

        	 	 	 	
          0.304

        	 	 	 	
          0.326

        	 	 	 	
          0.347

        	 	 	 	
          0.361

        	 
	
          18 months

        	 	 	
          0.146

        	 	 	 	
          0.179

        	 	 	 	
          0.211

        	 	 	 	
          0.242

        	 	 	 	
          0.271

        	 	 	 	
          0.298

        	 	 	 	
          0.322

        	 	 	 	
          0.345

        	 	 	 	
          0.361

        	 
	
          15 months

        	 	 	
          0.130

        	 	 	 	
          0.164

        	 	 	 	
          0.197

        	 	 	 	
          0.230

        	 	 	 	
          0.262

        	 	 	 	
          0.291

        	 	 	 	
          0.317

        	 	 	 	
          0.342

        	 	 	 	
          0.361

        	 
	
          12 months

        	 	 	
          0.111

        	 	 	 	
          0.146

        	 	 	 	
          0.181

        	 	 	 	
          0.216

        	 	 	 	
          0.250

        	 	 	 	
          0.282

        	 	 	 	
          0.312

        	 	 	 	
          0.339

        	 	 	 	
          0.361

        	 
	
          9 months

        	 	 	
          0.090

        	 	 	 	
          0.125

        	 	 	 	
          0.162

        	 	 	 	
          0.199

        	 	 	 	
          0.237

        	 	 	 	
          0.272

        	 	 	 	
          0.305

        	 	 	 	
          0.336

        	 	 	 	
          0.361

        	 
	
          6 months

        	 	 	
          0.065

        	 	 	 	
          0.099

        	 	 	 	
          0.137

        	 	 	 	
          0.178

        	 	 	 	
          0.219

        	 	 	 	
          0.259

        	 	 	 	
          0.296

        	 	 	 	
          0.331

        	 	 	 	
          0.361

        	 
	
          3 months

        	 	 	
          0.034

        	 	 	 	
          0.065

        	 	 	 	
          0.104

        	 	 	 	
          0.150

        	 	 	 	
          0.197

        	 	 	 	
          0.243

        	 	 	 	
          0.286

        	 	 	 	
          0.326

        	 	 	 	
          0.361

        	 
	
          0 months

        	 	 	
          —

        	 	 	 	
          —

        	 	 	 	
          0.042

        	 	 	 	
          0.115

        	 	 	 	
          0.179

        	 	 	 	
          0.233

        	 	 	 	
          0.281

        	 	 	 	
          0.323

        	 	 	 	
          0.361

        	 

   

  The exact Redemption Fair Market Value and Redemption Date may not be set forth in the table above, in which case, if the Redemption Fair Market Value is between two values in the table or the Redemption Date is between two redemption dates in the
    table, the number of Ordinary Shares to be issued for each Warrant exercised in a Make- Whole Exercise shall be determined by a straight-line interpolation between the number of shares set forth for the higher and lower Redemption Fair Market Values
    and the earlier and later redemption dates, as applicable, based on a 365- or 366-day year, as applicable.

   

  The share prices set forth in the column headings of the table above shall be adjusted as of any date on which the number of shares issuable upon exercise of a Warrant or the Exercise Price is adjusted pursuant to Section 4 hereof. If the
    number of shares issuable upon exercise of a Warrant is adjusted pursuant to Section 4 hereof, the adjusted share prices in the column headings shall equal the share prices immediately prior to such adjustment, multiplied by a fraction, the numerator
    of which is the number of shares deliverable upon exercise of a Warrant immediately prior to such adjustment and the denominator of which is the number of shares deliverable upon exercise of a Warrant as so adjusted. The number of shares in the table
    above shall be adjusted in the same manner and at the same time as the number of shares issuable upon exercise of a Warrant. If the Exercise Price is adjusted, (a) in the case of an adjustment pursuant to Section 4.4 hereof, the adjusted share prices
    in the column headings shall equal the share prices immediately prior to such adjustment multiplied by a fraction, the numerator of which is the higher of the Market Value and the Newly Issued Price and the denominator of which is $10.00 and (b) in the
    case of an adjustment pursuant to Section 4.1.2 hereof, the adjusted share prices in the column headings shall equal the share prices immediately prior to such adjustment less the decrease in the Exercise Price pursuant to such Exercise Price
    adjustment. In no event shall the number of shares issued in connection with a Make-Whole Exercise exceed 0.361 Ordinary Shares per Warrant (subject to adjustment). 

   

  
    
      

  

  6.3. Date Fixed for, and Notice of, Redemption; Redemption Price; Reference Value. In the event that the Company elects to redeem the Warrants pursuant to Sections 6.1 or 6.2, the Company shall fix a date for the redemption
    (the “Redemption Date”). Notice of redemption shall be mailed by first class mail, postage prepaid, by the Company not less than thirty (30) days prior to the Redemption Date (the “30-day Redemption Period”) to the Registered Holders of the Warrants to be redeemed at their last addresses as they shall appear on the registration books. Any notice mailed in the manner herein
    provided shall be conclusively presumed to have been duly given whether or not the Registered Holder received such notice. As used in this Agreement, (a) “Redemption Price” shall mean the
    price per Warrant at which any Warrants are redeemed pursuant to Sections 6.1 or 6.2.

   

  6.4. Exercise After Notice of Redemption. The Warrants may be exercised, for cash (or on a “cashless basis” in accordance with Section 6.2 of this Agreement) at any time after notice of redemption shall have been given by the Company
    pursuant to Section 6.3 hereof and prior to the Redemption Date. On and after the Redemption Date, the record holder of the Warrants shall have no further rights except to receive, upon surrender of the Warrants, the Redemption Price.

   

  6.5. Exclusion of Private Placement Warrants, Working Capital Warrants and Extension Warrants. The Company agrees that the redemption rights provided in Section 6.1 and Section 6.2 hereof shall not apply to the Private
    Placement Warrants, Working Capital Warrants or Extension Warrants if at the time of the redemption such Private Placement Warrants, Working Capital Warrants or Extension Warrants continue to be held by the Sponsor or its Permitted Transferees.
    However, once such Private Placement Warrants, Working Capital Warrants or Extension Warrants are transferred (other than to Permitted Transferees in accordance with Section 2.6 hereof), the Company may redeem the Private Placement Warrants,
    Working Capital Warrants or Extension Warrants pursuant to Section 6.1 or 6.2 hereof, provided that the criteria for redemption are met, including the opportunity of the holder of such Private Placement Warrants, Working Capital
    Warrants or Extension Warrants to exercise the Private Placement Warrants, Working Capital Warrants or Extension Warrants prior to redemption pursuant to Section 6.4 hereof. Private Placement Warrants, Working Capital Warrants or Extension
    Warrants that are transferred to persons other than Permitted Transferees shall upon such transfer cease to be Private Placement Warrants, Working Capital Warrants or Extension Warrants and shall become Public Warrants under this Agreement, including
    for purposes of Section 9.8 hereof. 

   

  
    7. Other Provisions Relating to Rights of Holders of Warrants.

  

   

  7.1. No Rights as Shareholder. A Warrant does not entitle the Registered Holder thereof to any of the rights of a shareholder of the Company, including, without limitation, the right to receive dividends, or other distributions, exercise any
    preemptive rights to vote or to consent or to receive notice as shareholders in respect of the meetings of shareholders or the election of directors of the Company or any other matter.

  

  

  7.2. Lost, Stolen, Mutilated, or Destroyed Warrants. If any Warrant is lost, stolen, mutilated, or destroyed, the Company and the Warrant Agent may on such terms as to indemnity or otherwise as they may in their discretion impose (which
    shall, in the case of a mutilated Warrant, include the surrender thereof), issue a new Warrant of like denomination, tenor, and date as the Warrant so lost, stolen, mutilated, or destroyed. Any such new Warrant shall constitute a substitute contractual
    obligation of the Company, whether or not the allegedly lost, stolen, mutilated, or destroyed Warrant shall be at any time enforceable by anyone.

   

  7.3. Reservation of Ordinary Shares. The Company shall at all times reserve and keep available a number of its authorized but unissued Ordinary Shares that shall be sufficient to permit the exercise in full of
    all outstanding Warrants issued pursuant to this Agreement.

   

  
    
      

  

  
    7.4. Registration of Ordinary Shares; Cashless Exercise at Company’s Option.

  

   

  7.4.1. Registration of the Ordinary Shares. The Company agrees that as soon as practicable, but in no event later than twenty (20) Business Days after the closing of its initial Business Combination, it shall use its commercially reasonable
    efforts to file with the Commission a registration statement for the registration, under the Securities Act, of the Ordinary Shares issuable upon exercise of the Warrants. The Company shall use its commercially reasonable efforts to cause the same to
    become effective within sixty (60) Business Days following the closing of its initial Business Combination and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration or redemption
    of the Warrants in accordance with the provisions of this Agreement. If any such registration statement has not been declared effective by the sixtieth (60th) Business Day following the closing of the initial Business Combination, holders of the
    Warrants shall have the right, during the period beginning on the sixty-first (61st) Business Day after the closing of the initial Business Combination and ending upon such registration statement being declared effective by the Commission, and
    during any other period when the Company shall fail to have maintained an effective registration statement covering the issuance of the Ordinary Shares issuable upon exercise of the Warrants, to exercise such Warrants on a “cashless basis,” by
    exchanging the Warrants (in accordance with Section 3(a)(9) of the Securities Act or another exemption) for that number of Ordinary Shares equal to the lesser of (A) the quotient obtained by dividing (x) the product of the number of Ordinary Shares
    underlying the Warrants, multiplied by the excess of the “Fair Market Value” (as defined below) less the Exercise Price by (y) the Fair Market Value and (B) 0.361 per Warrant. Solely for purposes of this subsection 7.4.1, “Fair Market Value” shall mean the volume-weighted average price of the Ordinary Shares as reported for the ten (10) trading day period ending on the trading day prior to the date that notice of
    exercise is received by the Warrant Agent from the holder of such Warrants or its securities broker or intermediary. The date that notice of “cashless exercise” is received by the Warrant Agent shall be conclusively determined by the Warrant Agent. In
    connection with the “cashless exercise” of a Public Warrant, the Company shall, upon request, provide the Warrant Agent with an opinion of counsel for the Company (which shall be an outside law firm with securities law experience) stating that (i) the
    exercise of the Warrants on a “cashless basis” in accordance with this subsection

  7.4.1 is not required to be registered under the Securities Act and (ii) the Ordinary
      Shares issued upon such exercise shall be freely tradable under United States federal securities laws by anyone who is not an affiliate (as such term is defined in Rule 144 under the Securities Act) of the Company and, accordingly, shall not be
      required to bear a restrictive legend. Except as provided in subsection 7.4.2, for the avoidance of doubt, unless and until all of the Warrants have been exercised or have expired, the Company shall continue to be obligated to comply with its
      registration obligations under the first three sentences of this subsection 7.4.1.

   

  7.4.2. Cashless Exercise at Company’s Option. If the Ordinary Shares are at the time of any exercise of a Public Warrant not listed on a national securities exchange such that they satisfy the definition of a “covered security” under Section
    18(b)(1) of the Securities Act, the Company may, at its option, (i) require holders of Public Warrants who exercise Public Warrants to exercise such Public Warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act as
    described in subsection 7.4.1 and (ii) in the event the Company so elects, the Company shall (x) not be required to file or maintain in effect a registration statement for the registration, under the Securities Act, of the Ordinary Shares
    issuable upon exercise of the Warrants, notwithstanding anything in this Agreement to the contrary, and (y) use its commercially reasonable efforts to register or qualify for sale the Ordinary Shares issuable upon exercise of the Public Warrant under
    applicable blue sky laws to the extent an exemption is not available.

  

  

  
    8. Concerning the Warrant Agent and Other Matters.

  

   

  8.1. Payment of Taxes. The Company shall from time to time promptly pay all taxes and charges that may be imposed upon the Company or the Warrant Agent in respect of the issuance or delivery of Ordinary Shares upon the exercise of the
    Warrants, but the Company shall not be obligated to pay any transfer taxes in respect of the Warrants or such shares.

   

  
    
      

  

  
    8.2. Resignation, Consolidation, or Merger of Warrant Agent.

  

  

  

  8.2.1. Appointment of Successor Warrant Agent. The Warrant Agent, or any successor to it hereafter appointed, may resign its duties and be discharged from all further duties and liabilities hereunder after giving sixty (60) days’ notice in
    writing to the Company. If the office of the Warrant Agent becomes vacant by resignation or incapacity to act or otherwise, the Company shall appoint in writing a successor Warrant Agent in place of the Warrant Agent. If the Company shall fail to make
    such appointment within a period of thirty (30) days after it has been notified in writing of such resignation or incapacity by the Warrant Agent or by the holder of a Warrant (who shall, with such notice, submit his, her or its Warrant for inspection
    by the Company), then the holder of any Warrant may apply to the Supreme Court of the State of New York for the County of New York for the appointment of a successor Warrant Agent at the Company’s cost. Any successor Warrant Agent, whether appointed by
    the Company or by such court, shall be a corporation or other entity organized and existing under the laws of the State of New York, in good standing and having its principal office in the United States of America, and authorized under such laws to
    exercise corporate trust powers and subject to supervision or examination by federal or state authority. After appointment, any successor Warrant Agent shall be vested with all the authority, powers, rights, immunities, duties, and obligations of its
    predecessor Warrant Agent with like effect as if originally named as Warrant Agent hereunder, without any further act or deed; but if for any reason it becomes necessary or appropriate, the predecessor Warrant Agent shall execute and deliver, at the
    expense of the Company, an instrument transferring to such successor Warrant Agent all the authority, powers, and rights of such predecessor Warrant Agent hereunder; and upon request of any successor Warrant Agent the Company shall make, execute,
    acknowledge, and deliver any and all instruments in writing for more fully and effectually vesting in and confirming to such successor Warrant Agent all such authority, powers, rights, immunities, duties, and obligations. 

   

  8.2.2. Notice of Successor Warrant Agent. In the event a successor Warrant Agent shall be appointed, the Company shall give notice thereof to the predecessor Warrant Agent and the Transfer Agent for the Ordinary
    Shares not later than the effective date of any such appointment.

   

  8.2.3. Merger or Consolidation of Warrant Agent. Any entity into which the Warrant Agent may be merged or with which it may be consolidated or any entity resulting from any merger or consolidation to which the
    Warrant Agent shall be a party shall be the successor Warrant Agent under this Agreement without any further act.

  

  

  
    8.3. Fees and Expenses of Warrant Agent.

  

   

  8.3.1. Remuneration. The Company agrees to pay the Warrant Agent reasonable remuneration for its services as such Warrant Agent hereunder and shall, pursuant to its obligations under this Agreement, reimburse the Warrant Agent upon demand
    for all expenditures that the Warrant Agent may reasonably incur in the execution of its duties hereunder.

  

  

  8.3.2. Further Assurances. The Company agrees to perform, execute, acknowledge, and deliver or cause to be performed, executed, acknowledged, and delivered all such further and other acts, instruments, and assurances as may reasonably be
    required by the Warrant Agent for the carrying out or performing of the provisions of this Agreement.

   

  
    8.4. Liability of Warrant Agent.

  

   

  8.4.1. Reliance on Company Statement. Whenever in the performance of its duties under this Agreement, the Warrant Agent shall deem it necessary or desirable that any fact or matter be proved or established by the Company prior to taking or
    suffering any action hereunder, such fact or matter (unless other evidence in respect thereof be herein specifically prescribed) may be deemed to be conclusively proved and established by a statement signed by the Chief Executive Officer, the Chief
    Financial Officer or the Chairman of the Board of the Company and delivered to the Warrant Agent. The Warrant Agent may rely upon such statement for any action taken or suffered in good faith by it pursuant to the provisions of this Agreement.

   

  8.4.2. Indemnity. The Warrant Agent shall be liable hereunder only for its own gross negligence, willful misconduct, fraud or bad faith. The Company agrees to indemnify the Warrant Agent and save it harmless against any and all liabilities,
    including judgments, out-of-pocket costs and reasonable outside counsel fees, for anything done or omitted by the Warrant Agent in the execution of this Agreement, except as a result of the Warrant Agent’s gross negligence, willful misconduct, fraud or
    bad faith.

  

  

  
    
      

  

  8.4.3. Exclusions. The Warrant Agent shall have no responsibility with respect to the validity of this Agreement or with respect to the validity or execution of any Warrant (except its countersignature thereof). The Warrant Agent shall not
    be responsible for any breach by the Company of any covenant or condition contained in this Agreement or in any Warrant. The Warrant Agent shall not be responsible to make any adjustments required under the provisions of Section 4 hereof or
    responsible for the manner, method, or amount of any such adjustment or the ascertaining of the existence of facts that would require any such adjustment; nor shall it by any act hereunder be deemed to make any representation or warranty as to the
    authorization or reservation of any Ordinary Shares to be issued pursuant to this Agreement or any Warrant or as to whether any Ordinary Shares shall, when issued, be valid and fully paid and nonassessable. 

   

  8.5. Acceptance of Agency. The Warrant Agent hereby accepts the agency established by this Agreement and agrees to perform the same upon the terms and conditions herein set forth and among other things, shall account promptly to the Company
    with respect to Warrants exercised and concurrently account for, and pay to the Company, all monies received by the Warrant Agent for the purchase of Ordinary Shares through the exercise of the Warrants.

   

  8.6. Waiver. The Warrant Agent has no right of set-off or any other right, title, interest or claim of any kind (“Claim”) in, or to any distribution of, the Trust Account (as
    defined in that certain Investment Management Trust Agreement, dated as of the date hereof, by and between the Company and Continental Stock Transfer & Trust Company as trustee thereunder) and hereby agrees not to seek recourse, reimbursement,
    payment or satisfaction for any Claim against the Trust Account for any reason whatsoever. The Warrant Agent hereby waives any and all Claims against the Trust Account and any and all rights to seek access to the Trust Account.

  

  

  
    9. Miscellaneous Provisions.

  

   

  9.1. Successors. All the covenants and provisions of this Agreement by or for the benefit of the Company or the Warrant Agent shall bind and inure to the benefit of their respective successors and assigns.

  

  

  9.2. Notices. Any notice, statement or demand authorized by this Agreement to be given or made by the Warrant Agent or by the holder of any Warrant to or on the Company shall be sufficiently given when so delivered if by hand or overnight
    delivery or if sent by certified mail or private courier service within five (5) days after deposit of such notice, postage prepaid, addressed (until another address is filed in writing by the Company with the Warrant Agent), as follows:

  

  

  Sculptor Acquisition Corp I

  9 West 57th Street, 39th Floor 

  New York, NY 10019

  Attn: Steven Orbuch

   

  

   with a copy to:

   

  

  Ropes & Gray LLP

  1211 Avenue of the Americas 

  New York, New York 10036 

  Attn: Michael Littenberg

   

  and

   

  Greenberg Traurig, LLP 

  MetLife Building

  200 Park Avenue 

  New York, NY 10166

   Attn: Joseph A. Herz

  

  

  Any notice, statement or demand authorized by this Agreement to be given or made by the holder of any Warrant or by the Company to or on the Warrant Agent shall be sufficiently given when so delivered if by hand or overnight delivery or if sent by
    certified mail or private courier service within five (5) days after deposit of such notice, postage prepaid, addressed (until another address is filed in writing by the Warrant Agent with the Company), as follows:

   

  Continental Stock Transfer & Trust Company 

  One State Street, 30th Floor

  New York, NY 10004

  Attention: Compliance Department

   

  
    
      

  

  9.3. Applicable Law. The validity, interpretation, and performance of this Agreement and of the Warrants shall be governed in all respects by the laws of the State of New York. Subject to applicable law, the Company hereby agrees that any
    action, proceeding or claim against it arising out of or relating in any way to this Agreement shall be brought and enforced in the courts of the State of New York or the United States District Court for the Southern District of New York, and
    irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive forum for any such action, proceeding or claim. The Company hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum.
    Notwithstanding the foregoing, the provisions of this paragraph will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal district courts of the United States of America are
    the sole and exclusive forum. Notwithstanding the foregoing, the provisions of this paragraph will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal district courts of the
    United States of America are the sole and exclusive forum. Any person or entity purchasing or otherwise acquiring any interest in the Warrants shall be deemed to have notice of and to have consented to the forum provisions in this Section 9.3. If any
    action, the subject matter of which is within the scope the forum provisions above, is filed in a court other than a court located within the State of New York or the United States District Court for the Southern District of New York (a “Foreign
      Action”) in the name of any warrant holder, such warrant holder shall be deemed to have consented to: (x) the personal jurisdiction of the state and federal courts located within the State of New York or the United States District Court for the
    Southern District of New York in connection with any action brought in any such court to enforce the forum provisions (an “Enforcement Action”), and (y) having service of process made upon such warrant holder in any Enforcement Action by service upon
    such warrant holder’s counsel in the Foreign Action as agent for such warrant holder.

   

  9.4. Persons Having Rights under this Agreement. Nothing in this Agreement shall be construed to confer upon, or give to, any person, corporation or other entity other than the parties hereto and the Registered Holders of the Warrants any
    right, remedy, or claim under or by reason of this Agreement or of any covenant, condition, stipulation, promise, or agreement hereof. All covenants, conditions, stipulations, promises, and agreements contained in this Agreement shall be for the sole
    and exclusive benefit of the parties hereto and their successors and assigns and of the Registered Holders of the Warrants.

  

  

  9.5. Examination of the Warrant Agreement. A copy of this Agreement shall be available at all reasonable times at the office of the Warrant Agent in the United States of America, for inspection by the Registered Holder of any Warrant. The
    Warrant Agent may require any such holder to submit such holder’s Warrant for inspection by the Warrant Agent.

   

  9.6. Counterparts. This Agreement may be executed in any number of original or facsimile counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but
    one and the same instrument.

   

  9.7. Effect of Headings; Interpretation. The section headings herein are for convenience only and are not part of this Agreement and shall not affect the interpretation thereof. References to “$” or “dollars” in this Agreement are to United
    States dollars.

   

  
    
      

  

  9.8.  Amendments. This Agreement may be amended by the parties hereto without the consent of any Registered Holder for the purpose of (i) curing any ambiguity or to correct any mistake, including to conform the provisions hereof to the
    description of the terms of the Warrants and this Agreement set forth in the Prospectus, or defective provision contained herein, (ii) amending the definition of “Ordinary Cash Dividend” as contemplated by and in accordance with the second sentence of
    subsection 4.1.2, (iii) making any amendments that are necessary in the good faith determination of the Board (taking into account then existing market precedents) to allow for the warrants to be classified as equity in the Company’s financial
    statements, provided that this clause (iii) shall not allow any modification or amendment to this Agreement that would adversely affect the rights of the Registered Holders, including by increasing the Exercise Price or shortening the Exercise Period,
    which shall require the vote or consent as provided in the immediately succeeding sentence, (iv) providing for the delivery of alternative issuance pursuant to Section 4.5 hereof or (v) adding or changing any provisions with respect to matters
    or questions arising under this Agreement as the parties may deem necessary or desirable and that the parties deem shall not adversely affect the rights of the Registered Holders under this Agreement. All other modifications or amendments, including
    any modification or amendment to increase the Exercise Price or shorten the Exercise Period and any amendment to the terms of only the Private Placement Warrants, Working Capital Warrants or Extension Warrants shall require the vote or written consent
    of the Registered Holders of 50% of the then-outstanding Public Warrants and, solely with respect to any amendment to the terms of the Private Placement Warrants, Working Capital Warrants or Extension Warrants or any provision of this Agreement with
    respect to the Private Placement Warrants, Working Capital Warrants or Extension Warrants, 50% of the then-outstanding Private Placement Warrants, Working Capital Warrants or Extension Warrants. Notwithstanding the foregoing, the Company may lower the
    Exercise Price or extend the duration of the Exercise Period pursuant to Sections 3.1 and 3.2, respectively, without the consent of the Registered Holders. 

  

  

  9.9. Severability. This Agreement shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof shall not affect the validity or enforceability of this Agreement or of any other term or provision hereof.
    Furthermore, in lieu of any such invalid or unenforceable term or provision, the parties hereto intend that there shall be added as a part of this Agreement a provision as similar in terms to such invalid or unenforceable provision as may be possible
    and be valid and enforceable.

  

  

  Exhibit A Form of Warrant Certificate

   

  Exhibit B Legend — Private Placement Warrants

  

  

  
    
      

  

  IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first above written.

  

  

  	 	
          SCULPTOR ACQUISITION CORP I

        
	 	 
	 	
          By:

        	
           /s/ Steven Orbuch

        	 
	 	 	
          Name: Steven Orbuch

        
	 	 	
          Title: Chief Executive Officer and Director

        

  

  

  	 	
          CONTINENTAL STOCK TRANSFER &

        
	 	
          TRUST COMPANY, as
              Warrant Agent

        
	 	 
	 	
          By:

        	
           /s/ Ana Gois

        	 
	 	 	
          Name: Ana Gois

        
	 	 	
          Title: Vice President

        

  

  

  
    [Signature Page to Warrant Agreement]

     

    

  

  
    
      

  

  EXHIBIT A

   

  [FACE]

   

   Number

  Warrants

   

  THIS WARRANT SHALL BE VOID IF NOT EXERCISED PRIOR TO 

  THE EXPIRATION OF THE EXERCISE PERIOD PROVIDED FOR 

  IN THE WARRANT AGREEMENT DESCRIBED BELOW

   

  Sculptor Acquisition Corp I

   Incorporated Under the Laws of the Cayman Islands

   

   CUSIP [●]

   

   Warrant Certificate

  

  

  This Warrant Certificate certifies that [ ], or registered
      assigns, is the registered holder of [ ] warrant(s) (the “Warrants” and each, a “Warrant”) to purchase Class A ordinary shares,
      with a par or nominal value of $0.0001 (“Ordinary Shares”), of Sculptor Acquisition Corp I, a Cayman Islands exempted company (the “Company”).
      Each Warrant entitles the holder, upon exercise during the period set forth in the Warrant Agreement referred to below, to receive from the Company that number of fully paid and nonassessable Ordinary Shares as set forth below, at the exercise price
      (the “Exercise Price”) as determined pursuant to the Warrant Agreement, payable in lawful money (or through “cashless exercise” as
      provided for in the Warrant Agreement) of the United States of America upon surrender of this Warrant Certificate and payment of the Exercise Price at the office or agency of the Warrant Agent referred to below, subject to the conditions set forth
      herein and in the Warrant Agreement. Defined terms used in this Warrant Certificate but not defined herein shall have the meanings given to them in the Warrant Agreement.

   

  Each whole Warrant is initially exercisable for one fully paid and non-assessable Ordinary Share. Fractional shares shall not be issued upon exercise of any Warrant. If, upon the exercise of Warrants, a holder would be entitled to receive a
    fractional interest in an Ordinary Share, the Company shall, upon exercise, round down to the nearest whole number the number of Ordinary Shares to be issued to the Warrant holder. The number of Ordinary Shares issuable upon exercise of the Warrants is
    subject to adjustment upon the occurrence of certain events as set forth in the Warrant Agreement.

  

  

  The initial Exercise Price per one Ordinary Share for any Warrant is equal to $11.50 per share. The Exercise Price is subject to adjustment upon the occurrence of certain events as set forth in the Warrant Agreement.

  

  

  Subject to the conditions set forth in the Warrant Agreement, the Warrants may be exercised only during the Exercise Period and to the extent not exercised by the end of such Exercise Period, such Warrants shall become void. The Warrants may be
    redeemed, subject to certain conditions, as set forth in the Warrant Agreement.

   

  Reference is hereby made to the further provisions of this Warrant Certificate set forth on the reverse hereof and such further provisions shall for all purposes have the same effect as though fully set forth at this place.

  

  

  This Warrant Certificate shall not be valid unless countersigned by the Warrant Agent, as such term is used in the Warrant Agreement. This Warrant Certificate shall be governed by and construed in accordance with the
    internal laws of the State of New York.

  

  

  
    
      

  

  	 	
          Sculptor Acquisition Corp I

        
	 	 	 
	 	
          By: 

        	 
	 	 	
          Name:

        
	 	 	
          Title: Director

        

  

  

  	 	
          CONTINENTAL STOCK TRANSFER & 

          TRUST COMPANY, AS WARRANT AGENT

        
	 	 	 
	 	
          By: 

        	 
	 	 	
          Name:

        
	 	 	
          Title:

        

   

  

  
    
      

  

  [Form of Warrant Certificate] [Reverse]

   

  The Warrants evidenced by this Warrant Certificate are part of a duly authorized issue of Warrants entitling the holder on exercise to receive [ ] Ordinary Shares and are issued or to be issued pursuant to a Warrant Agreement dated as of [ ],
    2021 (the “Warrant Agreement”), duly executed and delivered by the Company to Continental Stock Transfer & Trust Company, a New York corporation, as warrant agent (the “Warrant Agent”), which Warrant Agreement is hereby incorporated by reference in and made a part of this instrument and is hereby referred to for a description of the rights, limitation of rights,
    obligations, duties and immunities thereunder of the Warrant Agent, the Company and the holders (the words “holders” or “holder”
    meaning the Registered Holders or Registered Holder, respectively) of the Warrants. A copy of the Warrant Agreement may be obtained by the holder hereof upon written request to the Company. Defined terms used in this Warrant Certificate but not defined
    herein shall have the meanings given to them in the Warrant Agreement.

   

  Warrants may be exercised at any time during the Exercise Period set forth in the Warrant Agreement. The holder of Warrants evidenced by this Warrant Certificate may exercise them by surrendering this Warrant Certificate, with the form of Election
    to Purchase set forth hereon properly completed and executed, together with payment of the Exercise Price as specified in the Warrant Agreement (or through “cashless exercise” as provided for in the Warrant
    Agreement) at the principal corporate trust office of the Warrant Agent. In the event that upon any exercise of Warrants evidenced hereby the number of Warrants exercised shall be less than the total number of Warrants evidenced hereby, there shall be
    issued to the holder hereof or his, her or its assignee, a new Warrant Certificate evidencing the number of Warrants not exercised.

  

  

  Notwithstanding anything else in this Warrant Certificate or the Warrant Agreement, no Warrant may be exercised unless at the time of exercise (i) a registration statement covering the issuance of the Ordinary Shares to be issued upon exercise is
    effective under the Securities Act and (ii) a prospectus thereunder relating to the Ordinary Shares is current, except through “cashless exercise” as provided for in the Warrant Agreement.

  

  

  The Warrant Agreement provides that upon the occurrence of certain events the number of Ordinary Shares issuable upon exercise of the Warrants set forth on the face hereof may, subject to certain conditions, be adjusted. If, upon exercise of a
    Warrant, the holder thereof would be entitled to receive a fractional interest in an Ordinary Share, the Company shall, upon exercise, round down to the nearest whole number of Ordinary Shares to be issued to the holder of the Warrant.

  

  

  Warrant Certificates, when surrendered at the principal corporate trust office of the Warrant Agent by the Registered Holder thereof in person or by legal representative or attorney duly authorized in writing, may be exchanged, in the manner and
    subject to the limitations provided in the Warrant Agreement, but without payment of any service charge, for another Warrant Certificate or Warrant Certificates of like tenor evidencing in the aggregate a like number of Warrants.

   

  Upon due presentation for registration of transfer of this Warrant Certificate at the office of the Warrant Agent a new Warrant Certificate or Warrant Certificates of like tenor and evidencing in the aggregate a like number of Warrants shall be
    issued to the transferee(s) in exchange for this Warrant Certificate, subject to the limitations provided in the Warrant Agreement, without charge except for any tax or other governmental charge imposed in connection therewith.

  

  

  The Company and the Warrant Agent may deem and treat the Registered Holder(s) hereof as the absolute owner(s) of this Warrant Certificate (notwithstanding any notation of ownership or other writing hereon made by anyone), for the purpose of any
    exercise hereof, of any distribution to the holder(s) hereof, and for all other purposes, and neither the Company nor the Warrant Agent shall be affected by any notice to the contrary. Neither the Warrants nor this Warrant Certificate entitles any
    holder hereof to any rights of a shareholder of the Company.

  

  

  Election to Purchase

   

  

  
    
      

  

  (To Be Executed Upon Exercise of Warrant)

  

  

  The undersigned hereby irrevocably elects to exercise the right, represented by this Warrant Certificate, to receive [ ] Ordinary Shares and herewith tenders payment for such Ordinary Shares to the order of Sculptor Acquisition Corp I (the “Company”) in the amount of $[ ] in accordance with the terms hereof. The undersigned requests that the register of members of the Company be updated to reflect the issuance of such Ordinary Shares
    in the name of the undersigned and a certificate for such Ordinary Shares be registered in the name of [ ], whose address is [ ] and that such Ordinary Shares be delivered to [ ] whose address is [ ]. If said [ ] number of Ordinary Shares is less than
    all of the Ordinary Shares purchasable hereunder, the undersigned requests that a new Warrant Certificate representing the remaining balance of such Ordinary Shares be registered in the name of [ ], whose address is [ ] and that such Warrant
    Certificate be delivered to [ ], whose address is [ ].

   

  In the event that the Warrant is a Public Warrant that has been called for redemption by the Company pursuant to Section 6.2 of the Warrant Agreement and a holder thereof elects to exercise its Warrant pursuant to a Make-Whole Exercise, the
    number of Ordinary Shares that this Warrant is exercisable for shall be determined in accordance with Section 6.2 of the Warrant Agreement.

  

  

  In the event that the Warrant is a Private Placement Warrant that is to be exercised on a “cashless” basis pursuant to subsection 3.3.1(c) of the Warrant Agreement, the number of Ordinary Shares that this Warrant is exercisable for shall be
    determined in accordance with subsection 3.3.1(c) of the Warrant Agreement.

   

  In the event that the Warrant is to be exercised on a “cashless” basis pursuant to Section 7.4 of the Warrant Agreement, the number of Ordinary Shares that this Warrant is exercisable for shall be determined in accordance with Section
      7.4 of the Warrant Agreement.

   

  In the event that the Warrant may be exercised, to the extent allowed by the Warrant Agreement, through cashless exercise (i) the number of Ordinary Shares that this Warrant is exercisable for would be determined in accordance with the relevant
    section of the Warrant Agreement which allows for such cashless exercise and (ii) the holder hereof shall complete the following: The undersigned hereby irrevocably elects to exercise the right, represented by this Warrant Certificate, through the
    cashless exercise provisions of the Warrant Agreement, to receive Ordinary Shares. If said number of shares is less than all of the Ordinary Shares purchasable hereunder (after giving effect to the cashless exercise), the undersigned requests that a
    new Warrant Certificate representing the remaining balance of such Ordinary Shares be registered in the name of [ ], whose address is [ ] and that such Warrant Certificate be delivered to [ ], whose address is [ ].

  

  

  

  	[Signature Page Follows]
	
           

        	
           

        
	Date: [      ], 20	
           

        
	
           

        	(Signature)
	
           

        	
           

        
	 	(Address)
	 	 
	 	(Tax Identification Number)
	 	 
	Signature Guaranteed:	 
	 	 

  

  

  THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15
    UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED). 

  

  

  
    
      

  

  EXHIBIT B

  

  

  LEGEND

   

  THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE OFFERED, SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE
    SECURITIES ACT OF 1933, AS AMENDED, AND ANY APPLICABLE STATE SECURITIES LAWS OR AN EXEMPTION FROM REGISTRATION IS AVAILABLE. IN ADDITION, SUBJECT TO ANY ADDITIONAL LIMITATIONS ON TRANSFER DESCRIBED IN THE LETTER AGREEMENT BY AND AMONG SCULPTOR
    ACQUISITION CORP I (THE “COMPANY”), SCULPTOR ACQUISITION SPONSOR I AND THE OTHER PARTIES THERETO, THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD OR TRANSFERRED PRIOR TO THE
    DATE THAT IS THIRTY (30) DAYS AFTER THE DATE UPON WHICH THE COMPANY COMPLETES ITS INITIAL BUSINESS COMBINATION (AS DEFINED IN THE RECITALS OF THE WARRANT AGREEMENT REFERRED TO HEREIN) EXCEPT TO A PERMITTED TRANSFEREE (AS DEFINED IN SECTION 2 OF THE
    WARRANT AGREEMENT) WHO AGREES IN WRITING WITH THE COMPANY TO BE SUBJECT TO SUCH TRANSFER PROVISIONS.

   

  SECURITIES EVIDENCED BY THIS CERTIFICATE AND CLASS A ORDINARY SHARES OF THE COMPANY ISSUED UPON EXERCISE OF SUCH SECURITIES SHALL BE ENTITLED TO REGISTRATION RIGHTS UNDER A REGISTRATION AND SHAREHOLDER RIGHTS AGREEMENT TO BE EXECUTED BY THE COMPANY.

   

  NO. [    ] WARRANT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00337-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00337-of-00352.parquet"}]]